Omega Diagnostics Group Plc (ODX)

London
3.08
-0.03(-0.81%)
  • Volume:
    784,995
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    3.08 - 3.08

ODX Overview

Prev. Close
3.1
Day's Range
3.08-3.08
Revenue
5.73M
Open
3
52 wk Range
2.93-57.56
EPS
-0.02
Volume
784,995
Market Cap
7.32M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,589,943
P/E Ratio
-
Beta
4.28
1-Year Change
-92.62%
Shares Outstanding
237,685,180
Next Earnings Date
23 Nov 2022
What is your sentiment on Omega?
or
Market is currently closed. Voting is open during market hours.

Omega Diagnostics Group Plc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Omega Diagnostics Group Plc Analysis

Omega Diagnostics Group Plc Company Profile

Omega Diagnostics Group Plc Company Profile

Omega Diagnostics Group PLC is a United Kingdom-based medical diagnostics company. The principal activities of the Company and its subsidiaries are the manufacture, development and distribution of medical diagnostics products. The Company operates through two segments: Health and Nutrition and Global Health. The Health and Nutrition segment specializes in the research, development and production of kits to aid the detection of immune reactions to food. It also provides clinical analysis to the general public, clinics and health professionals as well as supplying the consumer Food Detective test. The Global Health segment specializes in the research, development, production and marketing of kits to aid the diagnosis of infectious diseases, including COVID-19. The Company's products include FoodPrint, Food Detective, CNS lab, VISITECT CD4 Advanced Disease, VISITECT COVID-19 IgM/IgA/IgG and VISITECT COVID-19 Antigen.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellStrong Sell
Technical IndicatorsBuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryBuyBuyNeutralStrong SellStrong Sell
  • Glad I got stopped out at 95p
    3
    • what a hero you are
      0
  • Here is a tip for you… look at the price of most pharma stocks before covid and thats whete they ate ahain now, or atlesdt heading that way. Full stop
    0
    • yes pretty disappointing for investors! & revenues are pretty much the same as it was despite 2 years of massive tailwinds!!!
      0
  • We definatly are not back🙈
    2
    • Finally we back
      1
      • 6 months too late.
        0
      • Let's see if we get some orders
        0
    • lifestyle company completely incapable of growth. Competence level of middle managers (or lower) running a listed company.
      0
      • The directors will soon be looking towards guarding their pay cheques so If they are going to raise money this current financia climate is not the best so the money vultures will be circlng for a heavy discount,larger than most expect with alllied dilution.Even then it will be difficult to look forward in business until the NHS mstter is fully dealt with.
        0
        • Amateurs. Utterly shambolic management.
          0
          • Here's to a new start, up and onwards.
            5
            • What makes you so certain?
              0
            • Good joke
              0
            • Definitely a good joke after todays decline. LOK
              0
          • Omega have taken “The Government” to court for failure to fulfill their contract for Omega to supply LFT’s. Then “The Government” demanding £2.5m repayment for the funds injected for equipment etc for the production of LFT’s 🤔
            0
            • no they haven't
              0
            • Clearly you did not read this, apologies that I stated going to court, but the rest is correct:Shares in Omega Diagnostics lost more than a quarter of their value yesterday after the company was hit with a £2.5 million bill for equipment to produce Covid tests that the UK Government no longer wants.The money was provided to Omega as a pre-production payment to ramp up capacity to make hundreds of millions of lateral flow antigen tests for the Department of Health and Social Care (DHSC). However, Omega confirmed last month that the contract has expired and will not proceed into Phase 2.The DHSC has now asked Omega to submit a proposal for returning the £2.5m pre-production payment made last year to purchase equipment for high-volume manufacturing at its headquarters in Alva.Having taken initial legal advice, Omega said it does not believe it is required to repay the money. It added that the board will continue to take further legal advice and hopes to reach a resolution “swiftly”
              0
            • It is clearly disappointing to receive this request for repayment given the efforts we have gone to ensure manufacturing capacity for Covid-19 lateral flow test was available for the DHSC and that we did not progress to Phase 2 of the contract due to the lack of confirmation from the DHSC regarding which test they require us to manufacture,” chief executive Colin King said.Acting in good faith we used these pre-production payments, along with our own funds, to upgrade our manufacturing facilities to be able to integrate the Government-furnished equipment and bringing on the additional staff required to be able to supply the DHSC using our UK-based volume manufacturing services. We therefore are confident that, having sought legal advice, we will not be required to make this repayment.”Announced in March 2020, the DHSC agreement could have been worth up to £374m.
              0
          • Martian invasion
            1